Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Assets (2016 - 2025)

Dare Bioscience's Non-Current Assets history spans 11 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 48.11% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $24.3 million, up 93.5%, while the annual FY2025 figure was $5.4 million, 48.11% up from the prior year.
  • Non-Current Assets reached $5.4 million in Q4 2025 per DARE's latest filing, down from $5.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q1 2025 to a low of $511161.0 in Q4 2021.
  • Average Non-Current Assets over 5 years is $2.6 million, with a median of $2.0 million recorded in 2022.
  • The largest YoY upside for Non-Current Assets was 374.67% in 2023 against a maximum downside of 37.58% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $511161.0 in 2021, then skyrocketed by 54.09% to $787630.0 in 2022, then skyrocketed by 374.67% to $3.7 million in 2023, then fell by 2.28% to $3.7 million in 2024, then skyrocketed by 48.11% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Non-Current Assets are $5.4 million (Q4 2025), $5.7 million (Q3 2025), and $6.4 million (Q2 2025).